SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare’s arm enters into strategic partnership with Orion Corporation

23 May 2025 Evaluate

Shilpa Medicare’s 100% subsidiary -- Shilpa Biocare has entered into a strategic partnership with Orion Corporation (Orion), a globally recognized pharmaceutical company headquartered in Finland, out-licensing its flagship product -- Recombinant Human Albumin -- for commercialisation across the European market. The product is currently under development.

Under this agreement, Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa’s Recombinant Human Albumin in Europe. Shilpa is entitled to receive from Orion certain development and regulatory milestone payments. Shilpa has been investing in the development of this novel product for about 8 years and has also set-up a large scale fermentation facility for manufacture of recombinant human albumin to address market demand for this life saving drug at a global scale. This collaboration marks a major milestone in Shilpa’s expansion into global biosimilar and biopharmaceutical markets, leveraging Orion’s strong regional presence, regulatory expertise, and well-established commercial infrastructure.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×